0001104659-23-117365.txt : 20231113
0001104659-23-117365.hdr.sgml : 20231113
20231113174401
ACCESSION NUMBER: 0001104659-23-117365
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231108
FILED AS OF DATE: 20231113
DATE AS OF CHANGE: 20231113
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lee Jennifer Kayden
CENTRAL INDEX KEY: 0001801372
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38223
FILM NUMBER: 231400363
MAIL ADDRESS:
STREET 1: C/O KRYSTAL BIOTECH, INC.
STREET 2: 2100 WHARTON STREET, SUITE 701
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
FORMER NAME:
FORMER CONFORMED NAME: Chien Jennifer
DATE OF NAME CHANGE: 20200128
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001649904
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462159271
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 BERKELEY STREET
STREET 2: 12TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 857-264-4280
MAIL ADDRESS:
STREET 1: 222 BERKELEY STREET
STREET 2: 12TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: RHYTHM METABOLIC, INC.
DATE OF NAME CHANGE: 20150803
4
1
tm2330582-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-11-08
0
0001649904
RHYTHM PHARMACEUTICALS, INC.
RYTM
0001801372
Lee Jennifer Kayden
222 BERKELEY STREET, 12TH FLOOR
BOSTON
MA
02116
0
1
0
0
EVP, Head of North America
1
Common Stock
2023-11-08
4
M
0
5712
6.8
A
7359
D
Common Stock
2023-11-08
4
S
0
3479
28.6429
D
3880
D
Common Stock
2023-11-08
4
S
0
2233
29.3129
D
1647
D
Common Stock
2023-11-09
4
M
0
3438
6.8
A
5085
D
Common Stock
2023-11-09
4
S
0
1719
27.3712
D
3366
D
Common Stock
2023-11-09
4
S
0
1719
28.00
D
1647
D
Stock Option (Right to Buy)
6.80
2023-11-08
4
M
0
5712
0
D
2032-02-08
Common Stock
5712
61880
D
Stock Option (Right to Buy)
6.80
2023-11-09
4
M
0
3438
0
D
2032-02-08
Common Stock
3438
58442
D
The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $28.04 to $29.01. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $29.04 to $29.70. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $26.86 to $27.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
/s/ Hunter Smith, Attorney-in-Fact for Jennifer Lee
2023-11-13